Phase 2 Study of 18F-DOPA PETCT Scan Added to Standard Imaging to Improve Management of Brain Tumors

What this Trial Is About

Researchers are evaluating whether adding 18F-DOPA positron emission tomography PETcomputed tomography CT scans to the standard imaging methods can better guide treatment for patients with brain tumors. This phase II trial aims to see if this combined PETCT scan improves clinical management in more than half of cases. The study also assesses the safety and how well this imaging technique detects tumors beyond what standard MRI scans show. In this study, patients receive an intravenous injection of the radioactive tracer 18F-DOPA and then undergo a PETCT scan lasting about 30 minutes on the first day. The PETCT combines functional imaging from PET with anatomical images from CT in one session. After the scan, patients are monitored for three days to observe any effects and to measure outcomes. Participants will be involved in the initial PETCT scan procedure and followed for safety and tumor detection outcomes for up to 64 days. Researchers will assess how the scan impacts clinical decisions three days after the scan and monitor any adverse events during this time. The study provides detailed imaging and clinical data to understand the potential benefits and safety of adding 18F-DOPA PETCT to brain tumor management.

An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors